Shiv Kapoor

Analyst Shiv Kapoor of Morgan Joseph reiterates his "buy" rating on Genzyme Corporation (NASDAQ: GENZ), while reducing his estimates for the company. The target price for GENZ is set to $76. Genzyme reported its Q4 EPS marginally ahead of the estimates. GENZ has issued its 2010 guidance short of...

Analyst Shiv Kapoor of Morgan Joseph maintains his "hold" rating on Myriad Genetics Inc (NASDAQ: MYGN), while raising his estimates for the company. According to Morgan Joseph, Myriad Genetics reported “strong” results for the December quarter. “We expect the stock to outperform in the short-term...